Adaptimmune Therapeutics Plc ADR (ADAP) concluded trading on Wednesday at a closing price of $0.31, with 6.75 million shares of worth about $2.09 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -67.91% during that period and on April 03, 2025 the price saw a gain of about 22.00%. Currently the company’s common shares owned by public are about 255.94M shares, out of which, 226.52M shares are available for trading.
Stock saw a price change of 32.58% in past 5 days and over the past one month there was a price change of -36.98%. Year-to-date (YTD), ADAP shares are showing a performance of -43.38% which decreased to -79.25% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $1.48 during that period. The average intraday trading volume for Adaptimmune Therapeutics Plc ADR shares is 1.62 million. The stock is currently trading -14.01% below its 20-day simple moving average (SMA20), while that difference is down -37.18% for SMA50 and it goes to -61.88% lower than SMA200.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) currently have 255.94M outstanding shares and institutions hold larger chunk of about 37.39% of that.
The stock has a current market capitalization of $78.06M and its 3Y-monthly beta is at 2.90. It has posted earnings per share of -$0.29 in the same period. It has Quick Ratio of 2.80 while making debt-to-equity ratio of 6.26. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADAP, volatility over the week remained 19.07% while standing at 14.46% over the month.
Stock’s fiscal year EPS is expected to drop by -62.07% while it is estimated to decrease by -348.37% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on July 30, 2024 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by Scotiabank stated Adaptimmune Therapeutics Plc ADR (ADAP) stock as a Sector outperform in their note to investors on May 30, 2024, suggesting a price target of $3.15 for the stock. On March 24, 2023, Bryan Garnier Initiated their recommendations, while on January 03, 2023, Guggenheim Upgrade their ratings for the stock with a price target of $5. Stock get a Buy rating from Mizuho on November 09, 2022.
